In vitro synergy with fosfomycin plus doxycyclin against linezolid and vancomycin-resistant Enterococcus faecium

J Glob Antimicrob Resist. 2020 Sep:22:78-83. doi: 10.1016/j.jgar.2020.01.014. Epub 2020 Jan 30.


Objective: Linezolid and vancomycin-resistant Enterococcus faecium (LRVREF) is globally emerging as a urinary nosocomial pathogen. A decrease in the amount of successful treatment options has created a necessity for the development of novel antimicrobial therapies. Combination therapy may provide an effective alternative for treatment. Fosfomycin and doxycyclin are currently used individually for the treatment of urinary tract infections. Fosfomycin has recently seen increased use because of its persistent activity against a large spectrum of multidrug-resistant organisms. The purpose of this study was to investigate the interaction of fosfomycin plus doxycyclin against LRVREF isolates.

Methods: MICs for fosfomycin and doxycyclin were determined for 24 unique clinical LRVREF isolates (4%, fosfomycin-susceptible; 92%, doxycyclin-susceptible). In vitro synergy testing with the combination of fosfomycin and doxycyclin was performed using an Etest method and time-kill assay.

Results: The combination of fosfomycin and doxycyclin demonstrated synergy with the Etest method in 11/24 (46%) isolates and in 10/24 (42%) isolates by the time-kill assay. Results from the Etest method and time-kill assay were in agreement for 7/24 (29.2%) of isolates. No antagonism was found.

Conclusions: The combination of fosfomycin and doxycyclin should be evaluated further with additional LRVREF isolates. In vivo studies should also be performed before use in clinical situations.

Keywords: Combination testing; Doxycyclin; Enterococcus; Fosfomycin; Synergy.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Enterococcus faecium*
  • Fosfomycin* / pharmacology
  • Linezolid / pharmacology
  • Vancomycin


  • Anti-Bacterial Agents
  • Fosfomycin
  • Vancomycin
  • Linezolid